Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2011-05-17
2011-05-17
Salimi, A R (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S007100, C435S007200, C435S007240, C435S041000, C435S325000
Reexamination Certificate
active
07943297
ABSTRACT:
A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a change in coreceptor usage from CCR5 to CXCR4. The change in coreceptor usage to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time.
REFERENCES:
patent: 5837464 (1998-11-01), Capon et al.
patent: 5851759 (1998-12-01), Weiner
patent: 5994515 (1999-11-01), Hoxie
patent: 6107019 (2000-08-01), Allaway et al.
patent: 7097970 (2006-08-01), Petropoulos et al.
patent: 7169551 (2007-01-01), Petropoulos et al.
patent: 2003/0180717 (2003-09-01), Esteban et al.
patent: 2005/0214743 (2005-09-01), Richman et al.
patent: 2006/0183110 (2006-08-01), Petropoulos et al.
patent: 2006/0223107 (2006-10-01), Chenna et al.
patent: 2009/0047662 (2009-02-01), Philpott et al.
patent: WO 99 14378 (1999-03-01), None
patent: 99/67429 (1999-12-01), None
patent: WO 00/65356 (2000-11-01), None
patent: WO 03/083094 (2003-10-01), None
Martinez et al. Human Immunodeficiency Virus Type 1 Genetic Evolution in Patients with Prolonged Suppression of Plasma Viremia. Virology 1999, vol. 256, pp. 180-187.
Yershov et al. DNA analysis and diagnostics on oligonucleotide microchips. The Proceedings from National Academy of Science, United States of America, May 1996, vol. 93, pp. 4913-4918.
Hung et al. Analysis of the Critical Domain in the V3 Loop of Human Immunodeficiency Virus Type 1 gp120 Involved in CCR5 Utilization. Journal of Virology, Oct. 1999, vol. 73, No. 10, p. 8216-8226.
Nelson, et al., “Evolutionary Variants of the Human Immunodeficiency Virus Type 1 V3 Region Characterized by Using a Heteroduplex Tracking Assay”, Journal of Virology, Nov. 1997, vol. 71, No. 11, pp. 8750-8758.
L. Q. Zhang, et al., “Selection of Specific Sequences in the External Envelope Protein of Human Immunodeficiency Virus Type 1 upon Primary Infection”, Journal of Virology, Jun. 1993, vol. 67, No. 6 pp. 3345-3356.
Shang Cao, et al., “Study on transient infection of T cell lines by M tropic HIV-1 strains”, Chinese Journal of Experimental and Clinical Virology, vol. 13, No. 2, Jun. 1999, pp. 163-169.
Shan Li, et al., “Persistent CCR5 Utilization and Enhanced Macrophage Tropism by Primary Blood Human Immunodeficiency Virus Type 1 Isolates from Advanced Stages of Disease and Comparison to Tissue-Derived Isolates”, Journal of Virology, Dec. 1999, vol. 73, No. 12, pates 9741-9755.
Julie A. E. Nelson, et al., “Patterns of Changes in Human Immunodeficiency Virus Type 1 V3 Sequence Populations Late in Infection”, Journal of Virology, Sep. 2000, vol. 74, No. 18, pp. 8494-8501.
Timothy J. Wilkin, et al., “HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211”, Clinical Infectious Diseases, Feb. 15, 2007, vol. 44, No. 4, pp. 591-595.
Charlotte Tscherning-Casper, et al., “Coreceptor Usage of HIV-1 Isolates Representing Different Genetic Subtypes Obtained From Pregnant Cameroonian Women”, Journal of Acquired Immune Deficiency Syndromes, vol. 24, No. 1, May 1, 2000, pp. 1-9.
Dalma Vodros et al., “Quantitative Evaluation of HIV-1 Coreceptor Usin in the GHOST (3) Cell Assay”, Virology, vol. 291, No. 1, Dec. 5, 2001, pp. 1-11.
Paul R. Gorry et al., “Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity”, Journal of Virology, Nov. 2001, vol. 75, No. 21, pp. 10073-10089.
Philpott S. et al. “Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.” J. Clin. Invest., vol. 107(4), Feb. 2001, p. 431-438.
Moore JP, et al. “Co-receptors for HIV-1 entry.” Cur. Opin. Immunol., vol. 9, 1997, pp. 551-562.
Callaway DS, et al. “Virus phenotype switching and disease progression in HIV-1 infection.” Proc. R. Soc. Lond., vol. 266, 1999 pp. 2523-2530.
Wodarz D, et al. “Defining CTL-induced pathology: implications for HIV.” Virology, vol. 274, Aug. 2000, pp. 94-104.
Clerici, et al. (2000) “Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group”. AIDS 14(2): 109-116.
Conner, et al. “Change in coreceptor use correlates with disease progression in HIV-1 infected individuals” J. Exp. Med. vol. 185(4). Feb. 17, 1997, pp. 621-628.
Bjomdal, et al. “Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype” Journal of Virology, Oct. 1997, pp. 7478-7487.
Burger and Weiser, (1997) “Biology of HIV-1 in women and men” Obstetrics and Gynecology Clinics of North America, vol. 24, No. 4, pp. 731-742.
Pierson, et al. (2000) “Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1”. J. Virol. 74(17): 7824-33.
Mosier (2000) “Virus and target cell evolution in human immunodeficiency virus type 1 infection”, Immunologic Research, vol. 21, No. 2-3, pp. 253-258.
Verrier, et al. (1999) “Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage” AIDS Research and Human Retroviruses, vol. 15, No. 9, 1999, pp. 731-743.
Chan, et al. (1999) “V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1” Journal of Virology, Mar. 1999, pp. 2350-2358.
Anderson, et al. (1998) “Early reduction of immune activation in lymphoid tissue following highly active HIV therapy” AIDS 12:F123-9.
Berger, et al. (1999) “Chemokine receptors as HIV-1-coreceptors: roles in viral entry, tropism and disease.” Arum. Rev. Immunol 17:657-700.
Berkowitz, et al. (2000) “Casual relationships between HIV-1 coreceptor utilization, tropism, and pathologenesis in human thymus.” J. AIDS Hum. Retro. 16(11):1039-45.
Cammack N. (1999) “Human Immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target.” Antivir. Chem. Chemother. 10(2):53-62.
Cecilia, et al. (2000) “Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India” Virology 271(2):253-8.
Dreyer, et al. (1999) “Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy.” AIDS Res. Hum. Retrovir 15(17):1563-1571.
Equils, et al. (2000) “Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.” J. Inf. Dis. 182:751-757.
Este, et al. (1999) “Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4”. J. Virol. 73:5577-85.
Fang, et al. (1996) “Molecular cloning of full-length HIV-1 genomes directly from plasma viral RNA”. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12(4):352-7.
Giovannetti, et al. (1999) “CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cel
Burger Harold
Kitchen Christina
Philpott Sean
Weiser Barbara
Health Research , Inc.
Humphrey Louise
Kowalski Thomas J.
Lu Deborah L.
Salimi A R
LandOfFree
Analysis of HIV-1 coreceptor use in the clinical care of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analysis of HIV-1 coreceptor use in the clinical care of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analysis of HIV-1 coreceptor use in the clinical care of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701865